关键数据
49.630今开
49.830最高
1.62M成交量
52.69市盈率 TTM
54.53市盈率动
--股息TTM
0.97%换手率
50.030昨收
48.520最低
59.71M成交额
22.36市盈率静
4.54市净率
0.00%股息率 TTM
4.82%ROA
40.79052周最高
0.68量比
367.07M净利润
167.54M总股本
0.9298每股收益TTM
0.31Beta
9.36%ROE
25.16552周最低
2.62%振幅
75.67%毛利率
8.22B总市值
-3.73回报/风险
2.23%风险率
操作建议
Alkermes Plc当前公司基本面数据相对健康,增长潜力很大。当前估值合理,在生物技术与医疗研究行业排名25/385位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价55.10。中期看,股价处于上升通道。近一个月,市场表现较差,但基本面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。
压力支撑

由于公司未披露,未能获取相关数据
Alkermes Plc新闻
即将为您带来更多新闻,敬请期待。。。
收益预测
Ionis Pharmaceuticals Inc
IONS
25
技术指标
财务指标
每股收益

由于公司未披露,未能获取相关数据
营业总收入

由于公司未披露,未能获取相关数据
Alkermes Plc简介
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
公司代码ALKS
公司Alkermes Plc
CEOPops (Richard F)
网址https://www.alkermes.com/
公司股东
常见问题
Alkermes Plc(ALKS)的当前股价是多少?
Alkermes Plc(ALKS)的当前股价是 48.99。
Alkermes Plc股票的52周最高点是多少?
Alkermes Plc股票的52周最高点是40.79。
Alkermes Plc股票的52周最低点是多少?
Alkermes Plc股票的52周最低点是25.16。
现在Alkermes Plc(ALKS)的股票是买入、持有还是卖出?
根据分析师评级,Alkermes Plc(ALKS)的总体评级为买入,目标价格为55.10。
Alkermes Plc(ALKS)股票的每股收益(EPS TTM)是多少
Alkermes Plc(ALKS)股票的每股收益(EPS TTM)是1.47。